ATE253116T1 - Verbesserte antikörper gegen ige und verfahren zur verbesserung von antikörpern - Google Patents

Verbesserte antikörper gegen ige und verfahren zur verbesserung von antikörpern

Info

Publication number
ATE253116T1
ATE253116T1 AT98932919T AT98932919T ATE253116T1 AT E253116 T1 ATE253116 T1 AT E253116T1 AT 98932919 T AT98932919 T AT 98932919T AT 98932919 T AT98932919 T AT 98932919T AT E253116 T1 ATE253116 T1 AT E253116T1
Authority
AT
Austria
Prior art keywords
antibodies
improvement
improved
against ige
antibodies against
Prior art date
Application number
AT98932919T
Other languages
English (en)
Inventor
Henry B Lowman
Leonard G Presta
Paula M Jardieu
John Lowe
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE253116T1 publication Critical patent/ATE253116T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
AT98932919T 1997-07-02 1998-06-30 Verbesserte antikörper gegen ige und verfahren zur verbesserung von antikörpern ATE253116T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/887,352 US5994511A (en) 1997-07-02 1997-07-02 Anti-IgE antibodies and methods of improving polypeptides
PCT/US1998/013410 WO1999001556A2 (en) 1997-07-02 1998-06-30 IMPROVED ANTI-IgE ANTIBODIES AND METHOD OF IMPROVING POLYPEPTIDES

Publications (1)

Publication Number Publication Date
ATE253116T1 true ATE253116T1 (de) 2003-11-15

Family

ID=25390964

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98932919T ATE253116T1 (de) 1997-07-02 1998-06-30 Verbesserte antikörper gegen ige und verfahren zur verbesserung von antikörpern

Country Status (28)

Country Link
US (4) US5994511A (de)
EP (1) EP0996728B1 (de)
JP (2) JP4286327B2 (de)
KR (1) KR100547538B1 (de)
CN (1) CN1260357C (de)
AR (2) AR013169A1 (de)
AT (1) ATE253116T1 (de)
AU (1) AU741115B2 (de)
BR (2) BR9810654B8 (de)
CA (1) CA2295540C (de)
CZ (1) CZ300724B6 (de)
DE (1) DE69819332T2 (de)
DK (1) DK0996728T3 (de)
ES (1) ES2210778T3 (de)
HU (1) HU228845B1 (de)
IL (2) IL133973A0 (de)
IS (1) IS2039B (de)
NO (1) NO324992B1 (de)
NZ (1) NZ501842A (de)
PL (1) PL194562B1 (de)
PT (1) PT996728E (de)
RO (1) RO120848B1 (de)
RU (1) RU2242515C2 (de)
SK (1) SK284395B6 (de)
TR (1) TR200000206T2 (de)
TW (2) TWI233946B (de)
WO (1) WO1999001556A2 (de)
ZA (1) ZA985500B (de)

Families Citing this family (188)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040197326A1 (en) * 1995-07-27 2004-10-07 Genentech, Inc. Method for treatment of allergic asthma
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US20040146507A1 (en) * 1996-11-27 2004-07-29 Genentech, Inc. Antibody mutants
US7122636B1 (en) 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
US6172213B1 (en) * 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
US5994511A (en) * 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US6504013B1 (en) 2000-02-01 2003-01-07 Idexx Laboratories, Inc. Canine allergy therapeutic recombinant chimeric anti-IgE monoclonal antibody
US7393529B2 (en) * 1998-04-09 2008-07-01 Idexx Laboratories, Inc. Methods and compositions for inhibiting binding of IgE to a high affinity receptor
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
US7759133B2 (en) * 1998-12-22 2010-07-20 Alk-Abello A/S Method of detecting and/or quantifying a specific IgE antibody in a liquid sample
GB9908533D0 (en) 1999-04-14 1999-06-09 Novartis Ag Organic compounds
US20020019009A1 (en) * 1999-12-09 2002-02-14 Roggen Erwin Ludo High throughput screening (HTS) assays
KR100771294B1 (ko) * 1999-12-14 2007-10-29 써모 바이오스타, 인크. 폴리펩티드 및 항원 안정화 희석제
EP1261376A1 (de) * 2000-01-27 2002-12-04 Genetics Institute, LLC Antikörper gegen ctla4(cd152), sie enthaltende konjugate und ihre verwendung
US7018801B2 (en) * 2000-02-11 2006-03-28 Board Of Regents, The University Of Texas System Selection of peptides with antibody-like properties
WO2001077182A1 (en) * 2000-04-07 2001-10-18 Matsushita Electric Industrial Co., Ltd. Antibody/carrier complex, process for producing the same, method of controlling antigen-antibody reaction by using the same and immunoassay method
US6951947B2 (en) * 2000-07-13 2005-10-04 The Scripps Research Institute Labeled peptides, proteins and antibodies and processes and intermediates useful for their preparation
US7176037B2 (en) * 2000-07-13 2007-02-13 The Scripps Research Institute Labeled peptides, proteins and antibodies and processes and intermediates useful for their preparation
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
AU2002213441B2 (en) † 2000-10-12 2006-10-26 Genentech, Inc. Reduced-viscosity concentrated protein formulations
PT1355919E (pt) * 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
AU2002240751A1 (en) * 2001-03-09 2002-09-24 William Herman Targeted ligands
US6966992B2 (en) * 2001-03-19 2005-11-22 Akzo Nobel Nv Method of purification of molecules using unbranched terminal alkyldiols
WO2002102303A2 (en) * 2001-05-01 2002-12-27 Medimmune, Inc. Crystals and structure of synagis fab
CA2445269A1 (en) * 2001-05-03 2002-11-14 Novartis Ag Anti-ige antibody to treat ocular allergies
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
AU2002316230A1 (en) * 2001-06-13 2002-12-23 Genentech, Inc. Methods of culturing animal cells and polypeptide production in animal cells
US20030073249A1 (en) * 2001-07-07 2003-04-17 Lee Duen Allergen detection chip
JP2003137804A (ja) * 2001-10-31 2003-05-14 Morinaga Milk Ind Co Ltd インターロイキン−１８誘導剤
US7179798B2 (en) * 2001-11-16 2007-02-20 Russell R. Roby Methods and compositions for the treatment of pain and other hormone-allergy-related symptoms using dilute hormone solutions
JP4063769B2 (ja) * 2001-12-28 2008-03-19 中外製薬株式会社 タンパク質安定化方法
CN1639185A (zh) * 2002-01-03 2005-07-13 斯克里普斯研究学院 癌相关表位
GB0200429D0 (en) * 2002-01-09 2002-02-27 Novartis Ag Organic compounds
US20050142539A1 (en) * 2002-01-14 2005-06-30 William Herman Targeted ligands
AU2003210802B2 (en) * 2002-02-05 2009-09-10 Genentech Inc. Protein purification
DK1495055T3 (da) * 2002-04-18 2013-11-11 Genencor Int Produktion af funktionelle antistoffer i filamentøse svampe
CA2490659C (en) * 2002-06-28 2014-08-19 Syed V. S. Kashmiri Humanized anti-tag-72 cc49 for diagnosis and therapy of human tumors
CA2505316C (en) * 2002-11-08 2014-08-05 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
ES2655912T3 (es) * 2002-11-08 2018-02-22 Ablynx N.V. Anticuerpos de dominio simple dirigidos contra factor de necrosis tumoral-alfa y usos para los mismos
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
US20060034833A1 (en) * 2002-11-08 2006-02-16 Els Beirnaert Single domain antibodies directed against interferron-gamma and uses therefor
WO2004041867A2 (en) * 2002-11-08 2004-05-21 Ablynx N.V. Camelidae antibodies against imminoglobulin e and use thereof for the treatment of allergic disorders
US20060034845A1 (en) 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
US20100003253A1 (en) * 2002-11-08 2010-01-07 Ablynx N.V. Single domain antibodies directed against epidermal growth factor receptor and uses therefor
US7056702B2 (en) * 2002-12-16 2006-06-06 Kimberly Clark Co Detecting lipocalin
US20060234296A1 (en) * 2003-02-01 2006-10-19 Sanjaya Singh Method for generating high affinity antibodies
SI2000481T1 (sl) * 2003-02-01 2016-08-31 Tanox, Inc. Anti-humana protitelesa IgE z visoko afiniteto
EP1602720B1 (de) * 2003-03-05 2010-11-03 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Verfahren zur herstellung eines heterologen proteins in e. coli
CN1798575A (zh) 2003-04-04 2006-07-05 健泰科生物技术公司 高浓度抗体和蛋白制剂
US20050158303A1 (en) * 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
GB2401040A (en) * 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
AU2004235595C1 (en) * 2003-04-30 2009-09-24 Japan Science And Technology Agency Human antihuman interleukin-18 antibody, fragment thereof and method of using the same
US20050026881A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-IgE antibody for treatment of asthma or chronic obstructive pulmonary disease
US20090263381A1 (en) * 2003-07-31 2009-10-22 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease
US20050065136A1 (en) * 2003-08-13 2005-03-24 Roby Russell R. Methods and compositions for the treatment of infertility using dilute hormone solutions
WO2005021594A2 (en) * 2003-08-29 2005-03-10 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Minimally immunogenic variants of sdr-grafted humanized antibody cc49 and their use
BRPI0414093A (pt) * 2003-09-05 2006-10-31 Scripps Res Insittute produtos de ozonização de colesterol para o tratamento e prevenção de ateroesclerose e/ou doenças cardiovasculares
WO2005023831A1 (en) * 2003-09-05 2005-03-17 The Scripps Research Institute Detection of cholesterol ozonation products
WO2005035721A2 (en) * 2003-10-08 2005-04-21 Ebioscience Native immunoglobulin binding reagents and methods for making and using same
WO2005035574A1 (ja) 2003-10-09 2005-04-21 Chugai Seiyaku Kabushiki Kaisha IgM高濃度安定化溶液
EP1735453A2 (de) * 2004-03-12 2006-12-27 The Scripps Research Institute Fluoreszenz-signale abgebende biosensor-moleküle und farbstoffe in lebenden zellen zum nachweis und zur quantifizierung von protein aktivitäten
US8398980B2 (en) 2004-03-24 2013-03-19 Chugai Seiyaku Kabushiki Kaisha Subtypes of humanized antibody against interleuken-6 receptor
US8435517B2 (en) 2008-09-17 2013-05-07 Xencor, Inc. Compositions and methods for treating IgE-mediated disorders
US20090111702A1 (en) * 2004-04-06 2009-04-30 Mount Sinai School Of Medicine Office Of Industrial Liason Methods of determining allergen response using microarray immunoassay techniques
WO2005105106A2 (en) * 2004-04-21 2005-11-10 Roby Russell R Hormone treatment of macular degeneration
GB0410627D0 (en) * 2004-05-12 2004-06-16 Scancell Ltd Specific binding members
US7604947B2 (en) * 2004-06-09 2009-10-20 Cornell Research Foundation, Inc. Detection and modulation of cancer stem cells
US8008447B2 (en) 2004-07-23 2011-08-30 Genentech, Inc. Crystallization of antibody or fragment thereof
US20060025390A1 (en) * 2004-07-28 2006-02-02 Roby Russell R Treatment of hormone allergy and related symptoms and disorders
US7662926B2 (en) 2004-09-02 2010-02-16 Genentech, Inc. Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
US7655229B2 (en) 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
CN101432019A (zh) * 2004-10-05 2009-05-13 泰勒公司 用抗IgE抗体治疗和预防接受替代治疗的患者体内的超敏反应和/或过敏症
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
BRPI0606867A2 (pt) * 2005-01-28 2009-07-21 Wyeth Corp formulação lìquida; forma de dosagem unitária farmacêutica; kit; recipiente; método para aumentar a estabilidade de um polipeptìdeo de ligação a antìgeno numa formulação; método para preparar uma forma de dosagem unitária farmacêutica; formulação estável; formulação; e produto terapêutico
GB0502358D0 (en) * 2005-02-04 2005-03-16 Novartis Ag Organic compounds
EP2336323A3 (de) 2005-03-25 2012-05-23 National Research Council Of Canada Verfahren zur Isolation von löslichen Polypeptiden
CA2606081C (en) 2005-04-26 2013-09-17 Markus M. Heiss Combination of the application of antibodies for immunostimulation together with glucocorticoids
WO2007032804A2 (en) * 2005-06-30 2007-03-22 Clifford Risk Novel uses for anti-ige therapy
HRP20140338T1 (hr) 2005-07-25 2014-06-20 Emergent Product Development Seattle, Llc Smanjenje broja b-stanica upotrebom molekula koje se specifiäśno vežu na cd37 i cd20
WO2008020827A2 (en) * 2005-08-01 2008-02-21 Biogen Idec Ma Inc. Altered polypeptides, immunoconjugates thereof, and methods related thereto
EP1941275B1 (de) * 2005-09-29 2013-07-24 Medimmune, Inc. Verfahren zur identifizierung membran-lg-spezifischer antikörper und verwendung davon zur ansteuerung immunglobulin produzierender vorläuferzellen
JP2007172129A (ja) * 2005-12-20 2007-07-05 Sony Corp 不揮発性メモリアクセス制御装置および不揮発性メモリ制御システム
CN101062949B (zh) * 2006-04-26 2011-07-27 上海抗体药物国家工程研究中心有限公司 重组抗人IgE单克隆抗体及其制备方法和用途
WO2007146968A2 (en) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
FR2902799B1 (fr) 2006-06-27 2012-10-26 Millipore Corp Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
EP2076287A2 (de) * 2006-10-12 2009-07-08 Wyeth Verfahren und zusammensetzungen mit verringerter opaleszenz
US8569464B2 (en) 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
WO2008079280A1 (en) 2006-12-21 2008-07-03 Millipore Corporation Purification of proteins
AR065368A1 (es) * 2007-02-15 2009-06-03 Astrazeneca Ab Anticuerpos para moleculas de ige
AU2008215926B2 (en) * 2007-02-15 2012-07-19 Astrazeneca Ab Binding members for IgE molecules
PT2132230E (pt) 2007-03-22 2014-07-17 Genentech Inc Anticorpos apoptóticos anti-ige que se ligam ao ige ligado a membrana
UY30994A1 (es) * 2007-04-02 2008-11-28 Amgen Fremont Inc Anticuerpos anti-ige
RS53008B2 (sr) † 2007-04-03 2022-12-30 Amgen Res Munich Gmbh Interspecijski specifičan cd3-epsilon vezujući domen
WO2008119566A2 (en) * 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific bispecific binders
EP2528002B1 (de) * 2007-04-16 2015-11-04 Momenta Pharmaceuticals, Inc. Definierte Glycoproteinprodukte und entsprechende Verfahren
EP2144628B1 (de) * 2007-05-08 2012-10-17 Genentech, Inc. Cystein-manipulierte anti-muc16-antikörper und antikörper-wirkstoff-konjugate
KR20190140090A (ko) 2007-07-09 2019-12-18 제넨테크, 인크. 폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지
CN101889025B (zh) 2007-10-30 2013-11-13 健泰科生物技术公司 通过阳离子交换层析进行的抗体纯化
US20110183861A1 (en) * 2008-01-29 2011-07-28 Ablynn N.V. Methods to stabilize proteins and polypeptides
US20220281964A1 (en) * 2008-02-25 2022-09-08 Xencor, Inc. Fc VARIANTS WITH ALTERED BINDING TO FcRn
EP2365003A1 (de) 2008-04-11 2011-09-14 Emergent Product Development Seattle, LLC CD37-Immuntherapeutikum und Kombination mit bifunktionellem Chemotherapeutikum davon
WO2009151514A1 (en) 2008-06-11 2009-12-17 Millipore Corporation Stirred tank bioreactor
IT1391559B1 (it) * 2008-09-01 2012-01-11 Lofarma Spa Allergoidi derivati da allergeni
EP2362767B1 (de) 2008-10-29 2017-12-06 Ablynx N.V. Formulierungen von einzeldomänen-antigen-bindungsmolekülen
BRPI0919879A2 (pt) 2008-10-29 2016-02-16 Wyeth Llc métodos para purificação de moléculas de ligação a antígeno de domínio único
RU2526156C2 (ru) * 2008-11-13 2014-08-20 ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ, ЭлЭлСи Cd37-иммунотерапевтическая комбинированная терапия и ее применения
EP2373689A1 (de) 2008-12-12 2011-10-12 MedImmune, LLC Kristalle und struktur einer humanen igg-fc-variante mit verst?rkter fcrn-bindung
CN102257122B (zh) 2008-12-16 2015-07-29 Emd密理博公司 搅拌槽反应器及方法
AR076640A1 (es) * 2009-03-06 2011-06-29 Genentech Inc Formulacion con anticuerpo. metodo para estabilizar anticuerpo. articulo de manufactura
EP2436397B1 (de) 2009-05-29 2017-05-10 Chugai Seiyaku Kabushiki Kaisha Pharmazeutische zusammensetzung mit einem antagonisten eines liganden der egf-familie als bestandteil
JP5787891B2 (ja) 2009-09-01 2015-09-30 ジェネンテック， インコーポレイテッド 改変されたプロテインａ溶離による向上したタンパク質精製
JP6139885B2 (ja) 2009-10-26 2017-05-31 ジェネンテック， インコーポレイテッド 治療的抗ＩｇＥ抗体に特異的な抗体を検出するためのアッセイ及びアナフィラキシーにおけるそれらの使用
HUE047173T2 (hu) 2010-03-01 2020-04-28 Bayer Healthcare Llc Optimalizált monoklonális ellenanyagok szöveti faktor útvonal inhibitor (TFPI) ellen
SG183867A1 (en) * 2010-03-11 2012-10-30 Rinat Neuroscience Corp ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
CN104998269B (zh) 2010-03-22 2019-06-11 弗·哈夫曼-拉罗切有限公司 对于稳定含有蛋白质的制剂有用的组合物和方法
EP2552967A4 (de) 2010-04-02 2014-10-08 Amunix Operating Inc Bindungsfusionsproteine, bindungsfusionsprotein-arzneimittelkonjugate, xten-arzneimittelkonjugate sowie verfahren zu ihrer herstellung und verwendung
BR112012025645A2 (pt) 2010-04-07 2017-12-12 Momenta Pharmaceuticals Inc glicanos de alta manose.
CN107312062B (zh) 2010-05-17 2021-03-16 Emd密理博公司 用于纯化生物分子的刺激响应性聚合物
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
RU2013120302A (ru) 2010-10-01 2014-11-20 Модерна Терапьютикс, Инк. Сконструированные нуклеиновые кислоты и способы их применения
TWI603738B (zh) 2010-11-08 2017-11-01 建南德克公司 皮下投予抗－ｉｌ－６受體抗體
US9170249B2 (en) 2011-03-12 2015-10-27 Momenta Pharmaceuticals, Inc. N-acetylhexosamine-containing N-glycans in glycoprotein products
EP2691101A2 (de) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
RU2013155695A (ru) 2011-06-30 2015-08-10 Дженентек, Инк. Препараты антител против с-мет
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2648950C2 (ru) 2011-10-03 2018-04-02 Модерна Терапьютикс, Инк. Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
CN104114572A (zh) 2011-12-16 2014-10-22 现代治疗公司 经修饰的核苷、核苷酸和核酸组合物
AR089434A1 (es) 2011-12-23 2014-08-20 Genentech Inc Procedimiento para preparar formulaciones con alta concentracion de proteinas
TWI593705B (zh) 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
KR20140119777A (ko) 2012-01-31 2014-10-10 제넨테크, 인크. 항-ig-e m1'' 항체 및 그의 사용 방법
WO2013120973A1 (en) * 2012-02-15 2013-08-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method of producing high-affinity antibodies
AU2013243948A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
NZ701915A (en) 2012-05-18 2016-11-25 Genentech Inc High-concentration monoclonal antibody formulations
US9695244B2 (en) 2012-06-01 2017-07-04 Momenta Pharmaceuticals, Inc. Methods related to denosumab
US20150140608A1 (en) * 2012-06-01 2015-05-21 Momenta Pharmaceuticals, Inc. Methods related to omalizumab
US20150210753A1 (en) 2012-07-26 2015-07-30 Momenta Pharmaceuticals, Inc. Glycoproteins with anti-inflammatory properties
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US10543278B2 (en) 2012-09-12 2020-01-28 Ramot At Tel-Aviv University Ltd. Immunoparticles and methods of generating and using same
WO2014081507A1 (en) 2012-11-26 2014-05-30 Moderna Therapeutics, Inc. Terminally modified rna
US9738722B2 (en) 2013-01-15 2017-08-22 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10450361B2 (en) 2013-03-15 2019-10-22 Momenta Pharmaceuticals, Inc. Methods related to CTLA4-Fc fusion proteins
WO2014186310A1 (en) 2013-05-13 2014-11-20 Momenta Pharmaceuticals, Inc. Methods for the treatment of neurodegeneration
KR101815265B1 (ko) 2013-06-20 2018-01-04 한올바이오파마주식회사 FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물
WO2015013668A1 (en) * 2013-07-26 2015-01-29 Ke Zhang Anti-immunoglobulin e antibodies and methods of use thereof
AU2014306867B2 (en) 2013-08-12 2017-10-26 Genentech, Inc. Compositions and method for treating complement-associated conditions
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
JP2016538829A (ja) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低密度リポタンパク質受容体をコードするポリヌクレオチド
EP3058084A4 (de) 2013-10-16 2017-07-05 Momenta Pharmaceuticals, Inc. Sialylierte glycoproteine
CN110627907B (zh) 2013-11-04 2024-03-29 艾科诺斯科技股份有限公司 重靶向t细胞的异源二聚免疫球蛋白的产生
MX2016006213A (es) 2013-11-13 2016-08-08 Genentech Inc Dispositivos inyectores manuales asistidos y metodos.
EP3137503A1 (de) 2014-05-01 2017-03-08 Genentech, Inc. Antifaktor-d-antikörpervarianten und verwendungen davon
WO2015195631A1 (en) * 2014-06-17 2015-12-23 Academia Sinica HUMANIZED ANTI-IgE ANTIBODIES THAT CROSSLINK CD23 ON B LYMPHOCYTES BUT DO NOT SENSITIZE MAST CELLS
BR112017000142B1 (pt) 2014-07-09 2021-08-17 Genentech, Inc Métodos para melhorar a recuperação por descongelamento de bancos de células e para congelamento de células cho para armazenamento, grupo de células cho para o congelamento de células de mamíferos, e banco de células
US20160060360A1 (en) 2014-07-24 2016-03-03 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
US11773166B2 (en) 2014-11-04 2023-10-03 Ichnos Sciences SA CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
WO2016164920A1 (en) 2015-04-09 2016-10-13 Cornell University Gene therapy to prevent reactions to allergens
EP3352760B1 (de) 2015-09-21 2026-03-11 Aptevo Research and Development LLC Cd3-bindende polypeptide
US10407510B2 (en) 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
WO2017075252A1 (en) * 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibody variant conjugates and uses thereof
GB201610198D0 (en) * 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
EP4434516A3 (de) 2016-07-18 2025-02-26 Ramot at Tel-Aviv University Ltd. Modulare plattform für gezielte therapeutika
JP7127859B2 (ja) 2016-11-09 2022-08-30 ノース カロライナ ステート ユニバーシティ キメラタンパク質を用いたアレルギー疾患の治療
MX2019007433A (es) 2016-12-22 2019-08-16 Genentech Inc Metodos y formulaciones para reducir el tiempo de reconstitucion de los polipeptidos liofilizados.
CA3063324A1 (en) 2017-05-16 2018-11-22 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
KR102631281B1 (ko) * 2017-08-10 2024-01-30 그리폴스 다이어그노스틱 솔루션즈 인크. 재조합 인간 cd38-세포외 도메인을 포함하는 조성물, 방법 및/또는 키트
KR102652133B1 (ko) * 2018-02-01 2024-03-29 베이징 카윈 테크놀로지 쉐어-홀딩 컴퍼니 리미티드 IL-4Rα 항체 및 그 용도
AU2019218128A1 (en) 2018-02-09 2020-09-17 Genentech, Inc. Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases
WO2019183437A1 (en) 2018-03-23 2019-09-26 North Carolina State University Methods and compositions for antibody to high affinity receptor for ige
WO2021250546A1 (en) 2020-06-09 2021-12-16 University Of Washington Micrornas as predictors of response to anti-ige therapies in chronic spontaneous urticaria
JP2023541217A (ja) * 2020-07-10 2023-09-29 シャンハイ ジェミンケア ファーマシューティカル カンパニー，リミティド 抗ＩｇＥ改変抗体及びその適用
CN111879923A (zh) * 2020-08-06 2020-11-03 深圳科隆生物新材料有限公司 一种可消除hama效应的试剂盒
WO2022192625A1 (en) 2021-03-11 2022-09-15 IgGenix, Inc. Methods and systems for predicting allergic response
CA3251445A1 (en) 2022-06-29 2024-01-04 Kashiv Biosciences, Llc IMPROVED ANTIBODY ASSAY METHOD
US12509529B2 (en) * 2024-05-17 2025-12-30 Excellergy, Inc. Antibodies and antibody fragments that bind IgE

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275149A (en) * 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
JPS6031471B2 (ja) * 1978-07-21 1985-07-22 協和醗酵工業株式会社 グリセロ−ル酸化酵素およびその製法
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5534617A (en) * 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
SU1752763A1 (ru) * 1990-04-10 1992-08-07 Центральный научно-исследовательский рентгено-радиологический институт Штамм гибридных культивируемых клеток животных MUS MUScULUS L. - продуцент моноклональных антител к I @ Е человека
CA2405246A1 (en) * 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
WO1992017207A1 (en) 1991-03-26 1992-10-15 Tanox Biosystems, Inc. MONOCLONAL ANTIBODIES WHICH BIND TO SECRETED AND MEMBRANE-BOUND IgE, BUT NOT TO IgE ON BASOPHILS
EP1400536A1 (de) * 1991-06-14 2004-03-24 Genentech Inc. Verfahren zur Herstellung humanisierter Antikörper
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
CA2113813C (en) * 1991-08-14 2005-04-12 Paula M. Jardieu Immunoglobulin variants for specific fc epsilon receptors
US5965709A (en) * 1991-08-14 1999-10-12 Genentech, Inc. IgE antagonists
US6329509B1 (en) * 1991-08-14 2001-12-11 Genentech, Inc. Anti-IgE antibodies
DE69232137T2 (de) * 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
AU675929B2 (en) * 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
ATE228536T1 (de) 1993-03-11 2002-12-15 Tanox Biosystems Inc Antigene epitope von ige repräsentierenden peptiden auf der b-zell-oberfläche aber nicht auf oberflächen von basophilen
US5597710A (en) * 1994-03-10 1997-01-28 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US5561053A (en) 1994-08-05 1996-10-01 Genentech, Inc. Method for selecting high-expressing host cells
US5705154A (en) * 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US6037453A (en) * 1995-03-15 2000-03-14 Genentech, Inc. Immunoglobulin variants
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
CA2229140A1 (en) * 1995-08-17 1997-02-27 Protein Design Labs, Inc. Anti-selectin antibodies for prevention of multiple organ failure and acute organ damage
US5994511A (en) * 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides

Also Published As

Publication number Publication date
EP0996728A2 (de) 2000-05-03
DE69819332D1 (de) 2003-12-04
ES2210778T3 (es) 2004-07-01
CA2295540A1 (en) 1999-01-14
PL338030A1 (en) 2000-09-25
HU228845B1 (en) 2013-06-28
HK1027833A1 (en) 2001-01-23
NO996551D0 (no) 1999-12-29
SK284395B6 (sk) 2005-03-04
US6290957B1 (en) 2001-09-18
TW570976B (en) 2004-01-11
HUP0002474A2 (hu) 2000-10-28
PT996728E (pt) 2004-03-31
WO1999001556A3 (en) 1999-04-22
JP2009055902A (ja) 2009-03-19
JP2002510211A (ja) 2002-04-02
AR060038A2 (es) 2008-05-21
US20030149244A1 (en) 2003-08-07
BRPI9810654C1 (pt) 2021-05-25
JP4371248B2 (ja) 2009-11-25
HUP0002474A3 (en) 2003-03-28
WO1999001556A2 (en) 1999-01-14
US20020054878A1 (en) 2002-05-09
PL194562B1 (pl) 2007-06-29
JP4286327B2 (ja) 2009-06-24
RU2242515C2 (ru) 2004-12-20
CN1268176A (zh) 2000-09-27
IS5321A (is) 1999-12-23
DE69819332T2 (de) 2004-07-15
IL133973A0 (en) 2001-04-30
TR200000206T2 (tr) 2000-07-21
IL133973A (en) 2006-12-10
CA2295540C (en) 2011-01-25
US5994511A (en) 1999-11-30
NO996551L (no) 2000-03-01
BR9810654B1 (pt) 2013-01-08
AR013169A1 (es) 2000-12-13
BR9810654A (pt) 2005-10-04
TWI233946B (en) 2005-06-11
CZ473599A3 (cs) 2000-06-14
KR20010014422A (ko) 2001-02-26
KR100547538B1 (ko) 2006-01-31
US6682735B2 (en) 2004-01-27
DK0996728T3 (da) 2004-02-23
SK187599A3 (en) 2001-08-06
NO324992B1 (no) 2008-01-14
AU741115B2 (en) 2001-11-22
RO120848B1 (ro) 2006-08-30
BR9810654B8 (pt) 2013-02-19
ZA985500B (en) 1999-12-24
NZ501842A (en) 2002-02-01
AU8270198A (en) 1999-01-25
US6761889B2 (en) 2004-07-13
CN1260357C (zh) 2006-06-21
IS2039B (is) 2005-08-15
CZ300724B6 (cs) 2009-07-29
EP0996728B1 (de) 2003-10-29

Similar Documents

Publication Publication Date Title
ATE253116T1 (de) Verbesserte antikörper gegen ige und verfahren zur verbesserung von antikörpern
DE69822270D1 (de) Verfahren und Einrichtung zur Hertellung von modifizierten Partikeln
DE69824312D1 (de) Verfahren und gerät zur beendigung von tachyarrhythmien
ATE251627T1 (de) Verfahren und kristallformen von 2- methylthienobenzodiazepinen
DE69823337D1 (de) Vorrichtung und verfahren zur rückgewinnung von puffern
DE19581886T1 (de) Verfahren und Zusammensetzung zur internen Identifikation von Proben
DE59810847D1 (de) Verfahren zur form- und volumengebung von humanhaaren
DE59806721D1 (de) Verfahren und vorrichtung zur präoperativen bestimmung der positionsdaten von endoprothesenteilen
CY2010017I2 (el) Νεα πρωτεϊνη και μεθοδος παρασκευης αυτης
DE69800630D1 (de) Chip zur elektroforetischen Trennung von Molekülen und Verfahren zur Verwendung desselben
DE69737258D1 (de) Verfahren und Vorrichtung zur Detektion von akutem myokardischem Infarkt
DE69618131D1 (de) Anordnung und Verfahren zur Betriebsmittelverwaltung von verteilten Objekten
DE69739122D1 (de) Verfahren und vorrichtung zur übertragung und programmladung von aufbereitungsinformationen
DE69834401D1 (de) Businterfacesystem und verfahren
DE69807220D1 (de) System und verfahren zur aufnahme von gebührenpflichtigen programmen
DE69835133T8 (de) Verfahren zur Bildinformationsverarbeitung und Verfahren zur Verhinderung von Fälschungen von Zertifikaten und dergleichen
ID17102A (id) Bahan berserat penghilang bau dan metoda pembuatannya
DE69619611D1 (de) Verfahren und Vorrichtung zur Bestimmung der petrologischen Eigenschaften von Schichtgesteinen
DE69739854D1 (de) System und verfahren zur bestimmung von spannungen
DE69822830D1 (de) Verfahren und vorrichtung zur bestimmung und charakterisierung von teilchen
DE69510174D1 (de) Verfahren und Reagenz zur Bestimmung von menschlichen Störungen
DE69728802D1 (de) Wirkstoffimmobilisierte Partikel und Verfahren zur Reinigung von Proteinen
DE69524161D1 (de) Verfahren zur Bestimmung von Fibrinogen und Reagenz zu dessen Bestimmung
DE69629021D1 (de) Verfahren und anordnung zur vorhersage von diastrophismus
DE59600121D1 (de) Verfahren und Vorrichtung zur Umlaborierung von Trägergeschossen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0996728

Country of ref document: EP